Consistent with the inverse expression correlation between RKIP and CCL5 in clinical samples, CCL5 expression showed an expression pattern opposite to that reported for RKIP in the same 81 samples from 70 breast cancer cell lines with elevated expression level in Basal, followed by Claudin-Low subtypes and the lowest expression level in the least aggressive Luminal subtype of breast cancer (Fig. 2c). This evidence concerns the gene PEBP1 and breast cancer.